Table: q1_q4_2022_prescription_drug_wac_increases , manufacturer_name like Z*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000082 Zydus Pharmaceuticals (USA) Inc. 06/30/2022 68382018701 Dipyridamole 25 mg Tablets 100 ct 05/05/2022 36.09 55.94 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None This is an AB rated generic drug that was not acquired in the last 5 years. This drug was discontinued in 2015 and obsoleted from the market in 2016 based on last lot expiration date. Zydus relaunched on May 5, 2022. There were no sales of this product in the last 5 years.
Rx0000082 Zydus Pharmaceuticals (USA) Inc. 06/30/2022 68382018801 Dipyridamole 50 mg Tablets 100 ct 05/05/2022 58.14 90.11 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None This is an AB rated generic drug that was not acquired in the last 5 years. This drug was discontinued in 2015 and obsoleted from the market in 2016 based on last lot expiration date. Zydus relaunched on May 5, 2022. There were no sales of this product in the last 5 years.
Rx0000082 Zydus Pharmaceuticals (USA) Inc. 06/30/2022 68382018901 Dipyridamole 75 mg Tablets 100 ct 05/05/2022 77.79 120.57 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None This is an AB rated generic drug that was not acquired in the last 5 years. This drug was discontinued in 2015 and obsoleted from the market in 2016 based on last lot expiration date. Zydus relaunched on May 5, 2022. There were no sales of this product in the last 5 years.
Rx0000163 Zyla Life Sciences 03/31/2022 69344010101 Indomethacin Oral Suspension 25 mg per 5mL - 237mL/Bottle 02/01/2022 194.10 2154.67 None Single Source Drug None 1 Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. None None None 01/31/2019 Iroko Pharmaceuticals, Inc 87000000 None What Zyla US Inc. has provided in Field #17 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs totaling approximately $125M: - Significant ongoing royalty payments on net sales - Additional debt burden of $55M and royalty payments associated with this debt - Cost of acquired inventory - Bankruptcy restructuring costs in connection with acquisition - Assumption of additional liabilities in connection with acquisition - Post-marketing and development costs - Commercial infrastructure costs - Intellectual Property litigation and maintenance costs - Costs to comply with regulatory requirements - Co-payment assistance program utilization costs - Significant increase in manufacturing costs 891.98 891.98 1985 232.17 None Comment on Data element #22 and #23: Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore, Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market and Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 4/2/2013).
Rx0000163 Zyla Life Sciences 03/31/2022 42211010111 Indomethacin Oral Suspension 25 mg per 5mL (237mL/Bottle) Disc NDC 02/01/2022 194.10 2154.67 None Single Source Drug None 1 Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. None None None 01/31/2019 Iroko Pharmaceuticals, Inc 87000000 None What Zyla US Inc. has provided in Field #17 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs totaling approximately $125M: - Significant ongoing royalty payments on net sales - Additional debt burden of $55M and royalty payments associated with this debt - Cost of acquired inventory - Bankruptcy restructuring costs in connection with acquisition - Assumption of additional liabilities in connection with acquisition - Post-marketing and development costs - Commercial infrastructure costs - Intellectual Property litigation and maintenance costs - Costs to comply with regulatory requirements - Co-payment assistance program utilization costs - Significant increase in manufacturing costs 891.98 891.98 1985 232.17 None Comment on Data element #22 and #23: Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore, Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market and Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 4/2/2013).
Rx0000163 Zyla Life Sciences 03/31/2022 69344011311 OXAYDO (Oxycodone HCL Tablet) 5 MG 100 CT BOTTLE 02/01/2022 87.81 974.74 03/16/2025 Single Source Drug None 1 Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. None None None None None None None None None None None None None This drug was not acquired in the past five years.
Rx0000163 Zyla Life Sciences 03/31/2022 69344021311 OXAYDO (Oxycodone HCL Tablet) 7.5 MG 100 CT BOTTLE 02/01/2022 131.56 1460.52 03/16/2025 Single Source Drug None 1 Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. None None None None None None None None None None None None None This drug was not acquired in the past five years.
Rx0000163 Zyla Life Sciences 03/31/2022 69344014443 Sprix 15.75mg/1 Spray, Metered (5 Bottles per Carton) 02/01/2022 144.97 2245.94 None Innovator Multiple Source Drug None 1 Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. None None None None None None None None None None None None None This drug was not acquired in the past five years.
Rx0000163 Zyla Life Sciences 03/31/2022 69344020429 Zorvolex 35 MG Capsule 90 EA 02/01/2022 70.72 785.07 04/23/2030 Single Source Drug None 1 Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. None None None 01/31/2019 Iroko Pharmaceuticals, Inc 87000000 None What Zyla US Inc. has provided in Field #17 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs totaling approximately $125M: - Significant ongoing royalty payments on net sales - Additional debt burden of $55M and royalty payments associated with this debt - Cost of acquired inventory - Bankruptcy restructuring costs in connection with acquisition - Assumption of additional liabilities in connection with acquisition - Post-marketing and development costs - Commercial infrastructure costs - Intellectual Property litigation and maintenance costs - Costs to comply with regulatory requirements - Co-payment assistance program utilization costs - Significant increase in manufacturing costs 383.05 350.14 2013 225.00 None Comment on Data element #22 and #23: Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore, Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market and Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 10/28/2013).
Rx0000163 Zyla Life Sciences 03/31/2022 42211020429 Zorvolex 35 MG Capsule 90 EA - Disc NDC 02/01/2022 70.72 785.07 04/23/2030 Single Source Drug None 1 Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products. None None None 01/31/2019 Iroko Pharmaceuticals, Inc 87000000 None What Zyla US Inc. has provided in Field #17 is an estimate of a portion of the purchase price of the product acquired from Iroko. This does not include the following additional costs totaling approximately $125M: - Significant ongoing royalty payments on net sales - Additional debt burden of $55M and royalty payments associated with this debt - Cost of acquired inventory - Bankruptcy restructuring costs in connection with acquisition - Assumption of additional liabilities in connection with acquisition - Post-marketing and development costs - Commercial infrastructure costs - Intellectual Property litigation and maintenance costs - Costs to comply with regulatory requirements - Co-payment assistance program utilization costs - Significant increase in manufacturing costs 383.05 350.14 2013 225.00 None Comment on Data element #22 and #23: Zyla utilized its access to pricing compendia (as well as solicited the assistance of a consultant) in order to provide values for these requests. Based on these searches, Zyla is unable to access WAC pricing for this product when introduced to the market. Therefore, Zyla provided the FDA Approval Date per the Orange Book for Year Drug Introduced to Market and Zyla provided the earliest WAC price readily accessible via pricing compendia portals for the NDC (in this case, 10/28/2013).